Natera announced the completion of enrollment to the randomized, double-blind phase III ALTAIR clinical trial. ALTAIR is the circulating tumor DNA, or ctDNA-guided treatment escalation arm of the CIRCULATE-Japan adaptive trial platform evaluating the utility of the Signatera molecular residual disease, or MRD, test in patients with stage II-IV resectable colorectal cancer, or CRC. CIRCULATE-Japan also includes the observational GALAXY study and the randomized phase III VEGA trial for ctDNA-guided treatment de-escalation. The company expects to share primary results from ALTAIR in mid-2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Craig-Hallum says CareDx appears to look to Congress for help amid Castle reversal
- CareDx announces district court upholds March 2022 jury verdict against Natera
- Natera announces ruling in favor of the company in CareDx false advertising case
- CareDx, Natera may have precedent to rebuke MolDx, says Craig-Hallum
- Natera assumed with an Overweight at JPMorgan